Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C14H15F2N3S.ClH |
Molecular Weight | 331.812 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NCC1=CNC(=S)N1[C@H]2CCC3=C(C2)C=C(F)C=C3F
InChI
InChIKey=DIPDUAJWNBEVOY-PPHPATTJSA-N
InChI=1S/C14H15F2N3S.ClH/c15-9-3-8-4-10(1-2-12(8)13(16)5-9)19-11(6-17)7-18-14(19)20;/h3,5,7,10H,1-2,4,6,17H2,(H,18,20);1H/t10-;/m0./s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/9283721Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25602710
https://www.ncbi.nlm.nih.gov/pubmed/24983834
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9283721
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25602710
https://www.ncbi.nlm.nih.gov/pubmed/24983834
Nepicastat (SYN-117) is a potent and selective inhibitor of dopamine-β-hydroxylase. This compound in Phase 2 of clinical trial for the treatment cocaine addiction and posttraumatic stress disorder.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23303068
Curator's Comment: Nepicastat is direct, competitive inhibitor of DBH that does not chelate copper, can cross the blood–brain barrier
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3102 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9283721 |
9.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
160 mg 1 times / day multiple, oral Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Co-administed with:: сocaine Sources: Page: p.8 |
unhealthy, ADULT n = 13 Health Status: unhealthy Condition: cocaine abuse Age Group: ADULT Sex: M+F Food Status: UNKNOWN Population Size: 13 Sources: Page: p.8 |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: https://clinicaltrials.gov/ct2/show/NCT01704196?term=NEPICASTAT&rank=3
Post Traumatic Stress Disorder: 120 mg/day
Cocaine Dependence: Nepicastat 120 mg and 100 mg riboflavin (once per day) for 11 weeks
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9283721
Nepicastat produced concentration-dependent inhibition of bovine and human dopamine-beta-hydroxylase activity. The calculated IC50s for nepicastat were 8.5+0.8 nM and 9.0+0.8 nM for the bovine and human enzyme, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9840545
Created by
admin on Sat Dec 16 05:01:11 GMT 2023 , Edited by admin on Sat Dec 16 05:01:11 GMT 2023
|
PRIMARY | |||
|
DTXSID00168811
Created by
admin on Sat Dec 16 05:01:11 GMT 2023 , Edited by admin on Sat Dec 16 05:01:11 GMT 2023
|
PRIMARY | |||
|
3WK068D17I
Created by
admin on Sat Dec 16 05:01:11 GMT 2023 , Edited by admin on Sat Dec 16 05:01:11 GMT 2023
|
PRIMARY | |||
|
170151-24-3
Created by
admin on Sat Dec 16 05:01:11 GMT 2023 , Edited by admin on Sat Dec 16 05:01:11 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD